Mark J. Hamblin

927 total citations
17 papers, 620 citations indexed

About

Mark J. Hamblin is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Immunology. According to data from OpenAlex, Mark J. Hamblin has authored 17 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 4 papers in Immunology. Recurrent topics in Mark J. Hamblin's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers), Biomarkers in Disease Mechanisms (3 papers) and Porphyrin Metabolism and Disorders (2 papers). Mark J. Hamblin is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers), Biomarkers in Disease Mechanisms (3 papers) and Porphyrin Metabolism and Disorders (2 papers). Mark J. Hamblin collaborates with scholars based in United States, United Kingdom and Netherlands. Mark J. Hamblin's co-authors include David J. Kelly, Maureen R. Horton, Jonathan G. Shaw, Danielle Antin‐Ozerkis, Martina Vašáková, Ganesh Raghu, Keith C. Meyer, Luca Richeldi, Lawrence Ho and Jeffrey A. Golden and has published in prestigious journals such as JAMA, Neurology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Mark J. Hamblin

16 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark J. Hamblin United States	9	342	202	170	73	69	17	620
Iliana Herrera Mexico	11	530 1.5×	107 0.5×	278 1.6×	102 1.4×	99 1.4×	24	904
Takahisa Takihara Japan	13	245 0.7×	173 0.9×	149 0.9×	31 0.4×	135 2.0×	28	612
Jing‐Yao Liu China	11	382 1.1×	55 0.3×	136 0.8×	32 0.4×	70 1.0×	27	625
Beatriz Ballester Spain	12	469 1.4×	149 0.7×	161 0.9×	48 0.7×	84 1.2×	22	700
Kazuyo Yamaji-Kegan United States	14	382 1.1×	98 0.5×	206 1.2×	13 0.2×	205 3.0×	18	682
Masayuki Sato Japan	11	116 0.3×	79 0.4×	121 0.7×	34 0.5×	85 1.2×	33	499
Abdelilah S. Gounni Canada	11	204 0.6×	357 1.8×	197 1.2×	66 0.9×	435 6.3×	22	840
Zdeňka Navrátilová Czechia	11	130 0.4×	80 0.4×	128 0.8×	34 0.5×	110 1.6×	28	406
Azumi Ueyama Japan	10	304 0.9×	83 0.4×	62 0.4×	52 0.7×	193 2.8×	18	589
Luxi Sun China	10	57 0.2×	91 0.5×	266 1.6×	40 0.5×	69 1.0×	18	507

Countries citing papers authored by Mark J. Hamblin

Since Specialization

Citations

This map shows the geographic impact of Mark J. Hamblin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Hamblin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Hamblin more than expected).

Fields of papers citing papers by Mark J. Hamblin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Hamblin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Hamblin. The network helps show where Mark J. Hamblin may publish in the future.

Co-authorship network of co-authors of Mark J. Hamblin

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Hamblin. A scholar is included among the top collaborators of Mark J. Hamblin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Hamblin. Mark J. Hamblin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Τzouvelekis, Αrgyris, Mark J. Hamblin, Won Il Choi, et al.. (2025). Late Breaking Abstract - ELEVATE IPF phase 2b open-label extension demonstrates durable efficacy of deupirfenidone. OA4456–OA4456.

2.

Maher, Toby M., Miguel Bergna, Amy Hajari Case, et al.. (2025). Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A7046–A7046. 1 indexed citations

3.

Hamblin, Mark J., et al.. (2023). Hypersensitivity Pneumonitis. Immunology and Allergy Clinics of North America. 43(2). 245–257. 2 indexed citations

4.

Raghu, Ganesh, Mark J. Hamblin, Alison Brown, et al.. (2022). Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research. 23(1). 129–129. 25 indexed citations

5.

Castillo, Sonia Velasco del, et al.. (2020). Assessment of Optimal Screening Tests for the Detection of an Inflammatory Myositis-associated Interstitial Lung Disease. Cureus. 12(4). e7875–e7875. 2 indexed citations

6.

Raghu, Ganesh, Bernt van den Blink, Mark J. Hamblin, et al.. (2019). Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. The Lancet Respiratory Medicine. 7(8). 657–664. 74 indexed citations

7.

Raghu, Ganesh, Bernt van den Blink, Mark J. Hamblin, et al.. (2019). Long-Term Safety and Efficacy of Recombinant Human Pentraxin-2 in Patients with Idiopathic Pulmonary Fibrosis. A2636–A2636. 1 indexed citations

8.

Raghu, Ganesh, Bernt van den Blink, Mark J. Hamblin, et al.. (2018). Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis. JAMA. 319(22). 2299–2299. 174 indexed citations

9.

Gelfand, Jeffrey M., Michael Bradshaw, Barney J. Stern, et al.. (2017). Infliximab for the treatment of CNS sarcoidosis. Neurology. 89(20). 2092–2100. 124 indexed citations

10.

Hamblin, Mark J., Michael Eberlein, Katharine E. Black, et al.. (2014). Lovastatin Inhibits Low Molecular Weight Hyaluronan Induced Chemokine Expression via LFA-1 and Decreases Bleomycin-Induced Pulmonary Fibrosis. International Journal of Biomedical Science. 10(3). 146–157. 8 indexed citations

11.

Hamblin, Mark J., Michael Eberlein, Katharine E. Black, et al.. (2014). Lovastatin Inhibits Low Molecular Weight Hyaluronan Induced Chemokine Expression via LFA-1 and Decreases Bleomycin-Induced Pulmonary Fibrosis.. PubMed. 10(3). 146–57. 8 indexed citations

12.

Black, Katharine E., Samuel L. Collins, Robert S. Hagan, et al.. (2013). Hyaluronan fragments induce IFNβ via a novel TLR4-TRIF-TBK1-IRF3-dependent pathway. Journal of Inflammation. 10(1). 23–23. 49 indexed citations

13.

Hamblin, Mark J. & Maureen R. Horton. (2011). Rheumatoid Arthritis-Associated Interstitial Lung Disease: Diagnostic Dilemma. Pulmonary Medicine. 2011. 1–12. 48 indexed citations

14.

Hamblin, Mark J., Jonathan G. Shaw, & David J. Kelly. (1993). Sequence analysis and interposon mutagenesis of a sensor-kinase (DctS) and response-regulator (DctR) controlling synthesis of the high-affinity C4-dicarboxylate transport system in Rhodobacter capsulatus. Molecular and General Genetics MGG. 237-237(1-2). 215–224. 35 indexed citations

15.

Shaw, Jonathan G., Mark J. Hamblin, & David J. Kelly. (1991). Purification, characterization and nucleotide sequence of the periplasmic C4‐dicarboxylate‐binding protein (DctP) from Rhodobacter capsulatus. Molecular Microbiology. 5(12). 3055–3062. 49 indexed citations

16.

Hamblin, Mark J., et al.. (1990). Mutagenesis, cloning and complementation analysis of C₄‐dicarboxylate transport genes from Rhodobacter capsulatus. Molecular Microbiology. 4(9). 1567–1574. 17 indexed citations

17.

Leyland, Mark L., Mark J. Hamblin, & David J. Kelly. (1989). Eubacterial isocitrate dehydrogenase with dual specificity for NAD and NADP fromRhodomicrobium vannielii. FEMS Microbiology Letters. 58(2-3). 165–169. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact